中國領先的結構性心臟病介入醫療器械供應商心泰醫療通過港交所聆訊
港交所官網顯示,心泰醫療通過港交所上市聆訊,中金公司為其獨家保薦人。
心泰醫療成立於1994年,致力於主要針對結構性心臟病的介入醫療器械的研發、生產及商業化,是中國最大的先天性心臟病封堵器產品及相關手術配套產品製造商,按2021年於中國銷售確認的收入計,其市場份額為38%。公司擁有全面的產品組合,20款已上市封堵器產品、9款封堵器在研產品以及21款主要心臟瓣膜在研產品,所有產品均為自主研發。根據弗若斯特沙利文報吿,按2021年中國先天性心臟病封堵器產品市場的市場份額計,心泰醫療是一家中國領先的先天性心臟病(“CHD”)(結構性心臟病的主要應用領域)介入醫療器械供應商,擁有廣泛的已上市及在研管線產品組合。
招股書顯示,公司的收入由2019年的1.165億元增加27.3%至2020年的1.482億元,進一步增加50.1%至2021年的2.226億元。此外據悉,上市公司樂普醫療是心泰醫療的控股股東,直接持有公司85.48%的股份,其在醫療器械市場具有強大市場及營銷資源,亦可助力公司未來的發展。
心泰醫療建立了具備強大研發、生產和商業化能力的綜合性及協同性平台,為公司的可持續增長作出貢獻。公司在北京及上海建立了研發中心,並就公司的已上市產品、在研產品及技術自主開發了廣泛且不斷髮展的知識產權組合,包括在中國的232項已註冊專利及51項待決專利申請。公司擁有30款處於不同開發階段的主要在研產品,包括生物可降解封堵器及心臟瓣膜在研產品,憑藉該等產品的獨特設計及先進功能,預期將在市場上處於有利競爭地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.